Atropine (Atropen®, Isopto Atropine®)

Drug Overview
Drug Class Antimuscarinics
Subclass Competitive Muscarinic Antagonist
Primary CV Use Symptomatic Bradycardia
Route IV / IM / SQ / Ophthalmic
Onset (IV) 1–2 minutes
Duration 30–60 minutes
Half-life ~2–4 hours
Metabolism Hepatic
Elimination Renal
Pregnancy Category C
Renal Adjustment No
Hepatic Adjustment No
Black Box Warning No
Controlled No

Overview

Atropine is a competitive antagonist of muscarinic acetylcholine receptors.

In cardiovascular practice, it is used to treat symptomatic bradycardia by blocking parasympathetic (vagal) tone at the SA and AV nodes.

It increases heart rate by removing inhibitory cholinergic signaling.


Mechanism of Action

Primary Target:

Normal Physiology:

Atropine Effect:

Net Effect:


Indications

Cardiovascular:

ACLS:

Other Uses:


Dosing

Adult (ACLS bradycardia):

Important:

If ineffective:


Contraindications

Absolute:

Relative / Cautions:


Adverse Effects

Common (anticholinergic effects):

Serious:

Mechanism-based:


Drug Interactions

Additive anticholinergic effects with:

Bradycardia context / AV node:


Monitoring


Clinical Pearls


Comparison Within Arrhythmia Management

Opposite AV nodal effects compared to:

Atropine: